{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:15:08Z","timestamp":1785806108067,"version":"3.56.0"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Fidaxomicin (FDX), a narrow-spectrum antibiotic recently shown to be superior to vancomycin in providing sustained clinical response to\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Clostridium difficile<\/jats:named-content>\n            infection, was investigated along with its major metabolite, OP-1118, with regard to their postantibiotic effects (PAE). FDX was found to have a prolonged PAE (10 h versus ATCC strains and 5.5 h versus a clinical isolate), and OP-1118's PAE was longer than that of the standard comparator, vancomycin (3 versus 0 to 1.5 h, respectively).\n          <\/jats:p>","DOI":"10.1128\/aac.00104-11","type":"journal-article","created":{"date-parts":[[2011,6,28]],"date-time":"2011-06-28T09:04:00Z","timestamp":1309251840000},"page":"4427-4429","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":54,"title":["Postantibiotic Effect of Fidaxomicin and Its Major Metabolite, OP-1118, against Clostridium difficile"],"prefix":"10.1128","volume":"55","author":[{"given":"Farah","family":"Babakhani","sequence":"first","affiliation":[{"name":"Optimer Pharmaceuticals, Inc., San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Gomez","sequence":"additional","affiliation":[{"name":"Optimer Pharmaceuticals, Inc., San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"Robert","sequence":"additional","affiliation":[{"name":"Optimer Pharmaceuticals, Inc., San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Sears","sequence":"additional","affiliation":[{"name":"Optimer Pharmaceuticals, Inc., San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2280-2282.2004"},{"key":"e_1_3_2_3_2","volume-title":"44th Intersci. Conf. Antimicrob. Agents Chemother","author":"Babakhani F.","year":"2004","unstructured":"BabakhaniF. ShangleS. RobertN. SearsP. ShueY. K.. 2004. Resistance development, cross-resistance, and synergy studies of OPT-80, abstr. E-2047. 44th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_4_2","volume-title":"44th Intersci. Conf. Antimicrob. Agents Chemother","author":"Babakhani F. K.","year":"2004","unstructured":"BabakhaniF. K. . 2004. Antimicrobial activity and postantibiotic effect of OPT-80, a new macrocyclic compound, against Clostridium difficile, abstr. E-2048. 44th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_5_2","volume-title":"Approved standard M11-A7","author":"CLSI","year":"2007","unstructured":"CLSI 2007. Methods for antimicrobial susceptibility testing of anaerobic bacteria; 7th ed. Approved standard M11-A7. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"7"},{"key":"e_1_3_2_6_2","first-page":"296","volume-title":"Antibiotics in laboratory medicine","author":"Craig W. A.","year":"1996","unstructured":"CraigW. A. GudmundssonS.. 1996. \u201cPostantibiotic effect,\u201d p. 296\u2013329. In LorianV. (ed.), Antibiotics in laboratory medicine, 4th ed. Williams and Wilkins Co., Baltimore, MD.","edition":"4"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4430-4434.2004"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4898-4902.2004"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01623-06"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00476-08"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01443-07"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910812"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.45753-0"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2010.485614"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000104471"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.9.1852"},{"key":"e_1_3_2_17_2","first-page":"526","article-title":"Clostridium difficile infection: new developments in epidemiology and pathogenesis","volume":"7","author":"Rupnik M.","year":"2009","unstructured":"RupnikM. WilcoxM. H. GerdingD. N.. 2009. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nature 7:526\u2013536.","journal-title":"Nature"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01045-07"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.042010-0"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00104-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00104-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:26:35Z","timestamp":1645485995000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00104-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1128\/AAC.00104-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.00104-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"2011-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-06-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-08-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}